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LETTERS TO THE EDITOR
Cyclooxygenase-2 in
Myocardial Ischemia: Is It Really a Friend?
We read with interest the elegant experimental study performed by
Shinmura et al. (1) and published in the Journal showing that
cyclooxygenase-2 (COX-2) inhibition prevents delayed ischemic
preconditioning and, in particular, reduction in postischemic
stunning. However, we believe it is unlikely that their experimental
findings have relevant clinical implications, as repeatedly suggested
by the investigators. Ischemic preconditioning has been shown to
reduce infarct size and myocardial stunning. However, the assess-
ment of infarct size is probably more complex than believed a few
years ago. Indeed, the majority of myocardiocytes are lost through
apoptosis (2,3), which is not assessed by standard techniques,
rather than through necrosis as previously thought. Therefore,
if assessment of infarct size is based solely on enzyme leakage
and/or on the extent of necrosis and fibrosis at pathology it does
not reflect total effective myocardiocyte loss. Notably, classic
studies on the effects of preconditioning on infarct size did not
take into account cell apoptosis, which might even be enhanced by
early or late ischemic preconditioning (2,4). Moreover, ischemic
preconditioning-induced reduction in stunning does not necessar-
ily have to be considered beneficial. The ischemic cell undergoes
both short- and long-term modifications to confront hypoxia, in a
delicate balance between survival and death (5,6). Stunning and
hibernation are natural responses to ischemia and are probably part
of the cellular mechanisms of adaptation aimed toward pro-
grammed cell survival after ischemia (5,6), whereas prolonged
ischemia (either with or without reperfusion) causes cell death.
Finally, and most importantly, recent data indicate that COX-2
is a mediator of ischemic damage. Takadera et al. (7) have shown
that COX-2 plays a key role in central nervous system apoptosis.
We have recently found that COX-2 expression in recent myo-
cardial infarction (MI) is associated with higher apoptotic rates (8);
Saito et al. (9,10), using an experimental model of MI, have
reported beneficial effects, in terms of postinfarction dysfunction,
of COX-2 inhibitors, and just recently high-dose aspirin was
found to protect myocardiocytes from apoptosis (11). Of note, in
a different experimental setting, Zhang et al. (12) found an increase
of COX-2 activity in genetically engineered animals prone to heart
failure, and, most interestingly, they describe beneficial effects of
selective COX-2 inhibition.
In conclusion, though COX-2 may provide a friendly protection
to ischemic myocardiocytes, as suggested by Shinmura and col-
leagues (1), evidence is still too scant to scientifically discard its
potential role as a foe leading to unfavorable outcomes in the
process of cardiac adaptation to ischemia. The present study by
Shinmura et al. (1) convincingly shows that COX-2 plays an active
role in myocardial response to ischemia and that inhibition of
COX-2 significantly affects the course of events after ischemic
insults. Whether the effect of COX-2 is beneficial or deleterious in
the clinical setting cannot be drawn from current data. Thus, the
statement that COX-2 inhibitors should be used with caution
because they may deprive the heart of its innate defensive response
is completely speculative to date as further studies are needed, and
COX-2 may ultimately be found to be more a “foe” than a “friend.”
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REPLY
We welcome the chance to reply to the letter of Dr. Abbate and
colleagues, as this gives us an opportunity to rectify a number of
common misconceptions. First, the assertion by Dr. Abbate and
colleagues that (following myocardial ischemia/reperfusion) “the
majority of myocardiocytes are lost through apoptosis” is not
supported by any evidence. Whereas apoptosis does occur after
acute myocardial ischemia and reperfusion (1), the quantitative
aspects of this process remain controversial and, at best, specula-
tive. Regardless, measurements of infarct size at 72 h after
reperfusion (as done by Shinmura et al. [2]) would include both
necrotic and apoptotic cell death. It is also incorrect to state that
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